Clinically relevant findings were identified in 88% of patients High-quality, durable EEG signals comparable to standard of care scalp monitor The Minder system is a designated Breakthrough Device and ...

Australia-based company Epiminder has received Food and Drug Administration (FDA) authorisation through the De Novo classification for its implantable continuous electroencephalogram (EEG) monitoring ...

Epiminder lists on Monday, having raised $125 million The company has developed a sub-scalp monitoring device for epilepsy Epiminder is one of two big-ticket biotech IPOs to grace the ASX next week ...

Epiminder, a pioneering medical device and information solutions company, announced that it has been granted FDA authorisation via the De Novo classification for Minder, its proprietary implantable ...

L-R: Epiminder non-executive director Robert Klupacs, chief medical officer and founder professor Mark Cook, and chairman Philip Binns prepare to ring the ceremonial bell as medical device company ...

Melbourne’s Epiminder, which counts the $18.6 billion Cochlear as its largest shareholder, has spent six years developing its sub-scalp device to detect seizures for epilepsy patients. Now it’s within ...

First clinical trial published demonstrating safety and efficacy of a bilateral continuous EEG monitoring system Clinically relevant findings were identified in 88% of patients High-quality, durable ...

Yet it lacks the celebrity advocacy of other maladies such as breast cancer and motor neurone disease. Famous epileptics from the history books include Theodore Roosevelt, Julius Caesar and Alexander ...